Afm13 clinical trial

Author: fykr

August undefined, 2024

WebJun 25, 2015 · CLINICAL TRIALS AND OBSERVATIONS June 25, 2015 A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma Clinical Trials & Observations Achim Rothe, Stephanie Sasse, Max S. Topp, Dennis A. Eichenauer, Horst Hummel, Katrin S. Reiners, Markus … WebAFM13 Lighting the way with clinical results: we are creating success with monotherapies and combination therapies. AFM13, a first-in-class ICE ® (innate cell engager) molecule targeting patients with CD30-positive lymphomas, 4 showed antitumor responses in a Phase 1/2 trial as a monotherapy in 15 patients with T-cell lymphomas and cutaneous …

Innate Cell Engagers - Affimed

WebJan 6, 2024 · REDIRECT, also known as AFM13-202 (NCT04101331), is a registration-directed phase 2 open-label, multicenter, global study investigating the efficacy and safety of AFM13 monotherapy in patients... la moderna bakery

Natural Killer Cells Complexed With a Bispecific Antibody May …

WebResearchers at Columbia University are carrying out an open-label Phase 1/2 clinical trial ( NCT03192202) assessing AFM13 as a therapy for CTCL in an estimated 18 patients. Other information AFM13 was designated an orphan drug by the U.S. Food and Drug Administration (FDA) in September 2009. *** WebApr 10, 2024 · Positive early results were observed in a phase 1/2 trial (NCT04074746) of the innate cell engager AMF13 and preactivated and expanded natural killer cells for patients with hevaily pretreated lymphoma, according to a presentation from the American Association for Cancer Research (AACR) 2024 Annual Meeting. 1. Investigators reported … WebTo assess the efficacy of the bispecific anti-CD30/CD16A, NK-cell engaging antibody AFM13 and to select the optimal treatment schedule (arm A-C), we initiated a randomized two … la moderna bakery menu

Registrational Trial of AFM13 Will Continue Following Success of ...

AFM13 - Immuno-Oncology News

WebAug 1, 2015 · Monoclonal antibodies against CD20 molecule have been leading the revolution of lymphoma treatment. In addition to monoclonal antibodies against CD20 and CD30, novel agents of immunotherapeutics in clinical development are being developed and are rapidly migrating to clinical application. One area of active development is NK … WebBuilding on this work we wished to clinically study adoptive AFM13-NK cell therapy in pts with R/R CD30+ lymphomas. METHODS: This single-center phase I-II trial … la moderna pastas wikipediaWebAFM13 was designed to attach to the CD30 protein on the surface of T-cell lymphoma cells and activate the immune system to recognize and destroy cancer cells. AFM13 is given … la moderna bakery- tamales

"WebApr 10, 2024 · The antibody, innate cell engager AFM13, acts as a bridge between the two cell types, helping the natural killer cells more effectively fight the cancer. Prior studies with AFM13 showed preliminary efficacy in clinical trials of patients with Hodgkin lymphoma, T-cell lymphoma, and peripheral T-cell lymphoma. " - Afm13 clinical trial

Afm13 clinical trial

AFM13: a first-in-class tetravalent bispecific anti-CD30/CD16A …

WebDec 7, 2024 · This updated analysis of the AFM13 monotherapy study in patients with relapsed or refractory CD30-positive lymphoma with cutaneous presentation showed an Objective Response Rate (ORR) of 42 percent (6/14) and demonstrated clinical activity after brentuximab vedotin failure in two of four patients. WebDec 10, 2024 · AFM13 is a first-in-class innate cell engager (ICE ®) that uniquely activates the innate immune system to destroy CD30-positive hematologic tumors. AFM13 induces specific and selective killing of CD30-positive tumor cells, leveraging the power of the innate immune system by engaging and activating natural killer (NK) cells and macrophages.

Did you know?

WebNov 8, 2024 · AFM13 is a first-in-class bispecific tetravalent ICE® molecule designed to bind with high affinity to CD16A on NK cells and macrophages and CD30 on lymphoma cells. … WebApr 10, 2024 · Affimed’s AFM13 is a proprietary bispecific antibody designed to bind to CD16A on NK cells and CD30 on lymphoma cells, allowing NK cells to eliminate cancer …

WebDec 10, 2024 · December 10, 2024, 2:20 PM · 9 min read Affimed N.V. AFM13 in combination with NK cells shows very high overall and complete response rates in 41 heavily pre-treated CD30-positive Hodgkin... WebGiving AFM13 loaded with NK cells followed by AFM13 alone may kill more cancer cells and decrease cancer growth in patients with CD30 positive AFM13-NK Hodgkin and Non …

WebThe purpose of this study is to learn about the effects of a research medicine called AFM13 and to see how well AFM13 is tolerated. Participation eligibility Participant eligibility … WebSep 24, 2024 · This is a phase II study to evaluate the antitumor activity and safety of AFM13 given as monotherapy in patients with CD30-positive T-cell lymphoma. The …

WebHeidelberg, Germany, April 10, 2024 – Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today provided a data update from the ongoing study of the Company’s lead innate cell engager (ICE®) AFM13 precomplexed with cord blood …

WebNov 19, 2024 · The combination of AFM13 with pembrolizumab demonstrated an objective response rate of 88% at the highest treatment dose, with an 83% overall response rate … la moderna panaderia san martinWebJan 28, 2016 · Brief Summary: The purpose of this study is to establish a dosing regimen for the combination therapy of AFM13 and pembrolizumab (MK-3475) in patients with relapsed or refractory (R/R) Hodgkin Lymphoma (HL) and to assess the safety and tolerability of this combination therapy. Condition or disease. la moderna guatemalaWebJan 28, 2016 · Brief Summary: The purpose of this study is to establish a dosing regimen for the combination therapy of AFM13 and pembrolizumab (MK-3475) in patients with relapsed or refractory (R/R) Hodgkin Lymphoma (HL) and to assess the safety and tolerability of this combination therapy. Study Design Go to la moderna zapateria durangoWebJul 1, 2024 · AFM13-NK complex cells exhibited enhanced responses to CD30+lymphomas in vitroand in vivo. Conclusions: We identify AFM13 as a promising combination with … jesianaWebNov 19, 2024 · Pharmacokinetic assessment of AFM13 in the combination setting revealed a half-life of up to 20.6 hours. This proof-of-concept study holds promise as a novel immunotherapy combination worthy of further investigation. This phase 1b study was registered at www.clinicaltrials.gov as NCT02665650 . © 2024 by The American Society … la moderna salamancaWebAFM13 in clinical trials A completed Phase 1 study ( NCT01221571) assessed the safety, tolerability, and activity of AFM13 in 28 patients with HL that returned despite treatment … jesiaWebAug 26, 2013 · In August 2013, LLS began its first European partnership with Affimed that supported two clinical trials for Hodgkin lymphoma (HL) patients. Expanding upon the initial work supported by LLS TAP, Affimed is currently enrolling "Bispecific NK Engager AFM13 Combined With NK Cells for Patients With Recurrent of Refractory CD30 Positive … jesi abitanti 2022